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Establishment of the milk-borne transmission as a key factor
for the peculiar endemicity of human T-lymphotropic
virus type 1 (HTLV-1):
the ATL Prevention Program Nagasaki
By Shigeo HINO*1,†
(Communicated by Takashi SUGIMURA, M.J.A.)
Abstract: In late 2010, the nation-wide screening of pregnant women for human T-
lymphotropic virus type 1 (HTLV-1) infection was implemented in Japan to prevent milk-borne
transmission of HTLV-1. In the late 1970s, recognition of the adult T-cell leukemia (ATL) cluster in
Kyushu, Japan, led to the discovery of the ﬁrst human retrovirus, HTLV-1. In 1980, we started to
investigate mother-to-child transmission (MTCT) for explaining the peculiar endemicity of
HTLV-1. Retrospective and prospective epidemiological data revealed the MTCT rate at 920%.
Cell-mediated transmission of HTLV-1 without prenatal infection suggested a possibility of milk-
borne transmission. Common marmosets were successfully infected by oral inoculation of HTLV-1
harboring cells. A prefecture-wide intervention study to refrain from breast-feeding by carrier
mothers, the ATL Prevention Program Nagasaki, was commenced in July 1987. It revealed a
marked reduction of HTLV-1 MTCT by complete bottle-feeding from 20.3% to 2.5%, and a
signiﬁcantly higher risk of short-term breast-feeding (<6 months) than bottle-feeding (7.4% vs.
2.5%, P < 0.001).
Keywords: breast milk, HTLV-1, infectious disease transmission-vertical, adult T-cell
leukemia, infection/prevention and control
Discovery of adult T-cell leukemia (ATL)
ATL was discovered by peculiar “ﬂower cells” in
1977.1) ATL is a very rare disease in Kyoto area,
where Prof. K. Takatsuki found that most ATL
patients were originated in Kyushu. Hematologists
in Kyushu had not recognized ATL as a distinct
disease entity, since ATL was popular in Kyushu. In
actuality, I found later that the total incidence of
leukemia/lymphoma in Nagasaki Prefecture in 1980s
was twice as much as that in the entire Japan, and
approximately one half of them were cases of ATL.
However, according to statistical data supplied by
National Cancer Center for 2009 does not give such a
distinct diﬀerence between Nagasaki Prefecture and
whole Japan. Since combined death rates of malig-
nant lymphoma and leukemia were 5.6 and 4.7 per
105, respectively, the excess deaths due to these
diseases in the Nagasaki Prefecture for the year 2009
can be calculated as only 13,2) which is far less than
100 diagnosed ATL cases per year in the Prefecture.3)
Because of the endemic nature of ATL, Prof. K.
Takatsuki assembled a group of collaborators to
search a causative agent. Prof. Y. Hinuma, an expert
in the ﬁeld of Epstein Barr virus (EBV), found an
antibody detected in all ATL patients and with high
frequency in their family members by an indirect
immunoﬂuorescence test.4) The target cell in the test,
MT-1, had been established by Prof. I. Miyoshi5)
without knowledge of the distinct entity of ATL.
Type C particles were found in MT-1 cells after
treatment with iododeoxyuridine (IUdR).4) Later,
the virus was identiﬁed as the ﬁrst human infectious
retrovirus; it had a novel distinct gene, pX.6) The
virus was named as “ATL virus (ATLV)” by this
group. However, the current terminology, human
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throughout this article after nomenclature by Inter-
national Committee on Taxonomy of Virus.7)
The ﬁrst human retrovirus
Retroviruses have been known as oncogenic
since the discovery of Rous sarcoma virus in the
early 1900s. A wide variety of animal retroviruses
has been described up to the present. Searches for
a responsible retrovirus in human cancers were
attempted extensively. The “oncogene theory” by
Huebner and Todaro in 19698) accelerated the
competition even further. Hundreds of published
and unpublished human retroviruses have been
‘isolated’ from “human sources”, but these inferred
“novel human viruses” were identiﬁed as laboratory
contaminations without any exception. The hope
for ﬁnding a human retrovirus was almost dying at
the end of 1970s. Therefore, the discovery of a new
retrovirus from a culture of Sezary syndrome in
19809) did not attract enough attentions by itself.
Although Prof. Y. Hinuma's report published in
19811) did not carry enough information to establish
the discovery of a novel human retrovirus, it
contained an important evidence: the association of
a speciﬁc type of human leukemia, ATL, with an
antibody against MT-1 cells which harbored an
inducible C-type virus. The discovery of another
human retrovirus, human immunodeﬁciency virus
(HIV), followed in 1983. Surprisingly, HIV contained
a gene similar to the pX of HTLV-1, even though
these two viruses are taxonomically classiﬁed into
diﬀerent genera, deltaretrovirus and lentivirus, re-
spectively.7)
Group meeting of HTLV-1 at Kyoto University
in the fall of 1980
I knew nothing about ATL when I joined
the laboratory of Prof. T. Miyamoto at Nagasaki
University in the early 1980. In the fall of 1980, Prof.
Y. Hinuma invited Prof. T. Miyamoto to a group
meeting at Kyoto University on the recently discov-
ered human retrovirus, HTLV-1. Prof. T. Miyamoto
had worked for Prof. Y. Hinuma at Tohoku
University. He was asked to survey the transmission
pathway of HTLV-1, because Nagasaki was located
in the center of HTLV-1 endemy.4),10)
Prof. T. Miyamoto sent me to the meeting. The
information on the new human retrovirus presented
at the meeting excited me promptly. The high
frequency of lymphatic leukemia in Kyushu reminded
me a comment of my hematologist father some 50
years ago that the bone-marrow involvement in
leukemic patients in Kyushu was signiﬁcantly lower
than that in those from other regions of Japan. Virus
carriers have antibodies against the virus detectable
by the indirect immunoﬂuorescence test, and there-
fore, carriers in general population were easily
screened. Virus carriers were distinctly more preva-
lent in Kyushu, and they were clustered heavily in
the family members of ATL patients, implying that
the viral transmission was more frequent within
family members. While the prevalence of HTLV-1
in the husbands of carrier wives was no higher than
that in the general population, wives of carrier
husbands were almost invariably infected among
senile populations, suggesting a male-to-female sex-
ual transmission.10) However, because the prevalence
in females was indistinct before forties, the eﬃciency
of male-to-female transmission seems to be relatively
ineﬃcient.
The virus was transmitted with whole blood
transfusion; as much as 60% of recipients were
infected after one unit (200mL) of transfusion,
but not through fresh plasma infusion.11) In vitro
infection experiments revealed that the virus is easily
transmissible by co-culture of infected cells with fresh
lymphocytes in the presence of IL-2, but not by
inoculation with infected culture ﬂuid. These lines of
evidence have suggested that infection of the virus is
cell-associated, requiring the direct contact of donor’s
infected living cells with uninfected recipient’s cells.
On the way back to Nagasaki from the meeting
Excited with a prospect that I have ﬁnally found
my life-long project, “to determine the transmission
pathway of HTLV-1”, I went back to Nagasaki asking
questions to myself. Why HTLV-1 was kept endemic
in Kyushu, especially in rural areas? The endemic
feature of most microorganisms became less clear
in modern communities due to busy human and
material traﬃcs. Most pathogens still endemic are
usually dependent on vectors, such as animals or
insects. Most of these endemic diseases have been
wiped out or became rare in the contemporary Japan.
A pathogen could be localized in a certain region, if it
were recently introduced into the community. But it
would be more often in major cities or surrounding
areas, not in rural areas. Therefore, HTLV-1 has
probably been present historically in rural areas, and
stayed there for a long period without free exporta-
tion. Because of a relative ineﬃciency in trans-
missions, the virus probably remained dormant, even
if it had been exported into new areas.
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lies of ATL patients suggested an intrafamilial
transmission. If a microorganism is spread mainly
by the sexual transmission, sooner or later it should
be spread around the world as other sexually trans-
mitted diseases. Ineﬃciency of sexual transmission in
HTLV-1 was consistent with the endemicity. What is
a more intimate relation than husband and wife?
Because intrafamilial transmissions via aerosol, drop-
let or direct contact should be also common in other
relationships, such as siblings and classmates, these
common transmission pathways are unlikely as the
leading candidate. If transmissions among siblings
are common, they should be common also in nurseries
and schools, diluting the inﬂuence of intrafamilial
transmissions.
Retroviruses lose the infectivity more rapidly
than other RNA viruses, such as inﬂuenza virus,
probably because the viral reverse transcriptase
indispensable for viral infection is unstable. Because
HTLV-1 is strongly cell-associated, transmission of
HTLV-1 needs the transfer of live infected cells.
Keeping T-lymphocytes alive outside the body is
trickier than maintaining virus particles alive, even in
optimized experimental conditions. Therefore, trans-
fer of live T-lymphocytes from donor to recipient
should require the direct exchange of body-ﬂuids.
I came to a conclusion that the best candidate for
transferring signiﬁcant amount of body ﬂuid should
be in the intimate relation between mother and child.
I went on to setup a ﬁeld experiment to provide
a hard evidence of MTCT as the major cause of
HTLV-1 endemy.
Later, at one of conventions for Japanese Cancer
Association, one of attendant doctors came to me,
and insisted the possibility of mosquito-borne in-
fection to explain the endemicity of HTLV-1. The
endemic feature in Kyushu, representing the south-
western hot region, was consistent with this assump-
tion. I had discarded the possibility by three reasons.
Blood volume carried by mosquito would be too small
for cell-mediated transmissions. Survival of human
T-lymphocyes within the body of mosquito should
be diﬃcult. If HTLV-1 replicates in mosquito cells,
the cell-to-cell infection from mosquito cells back
to a new human recipient is necessary. Above all,
mosquitos cannot explain the familial clustering of
carriers.
Endogenous and infectious retroviruses
Animal retroviruses are classiﬁed into two
categories, endogenous and infectious. Endogenous
viruses reside as the proviral DNA covalently
integrated in chromosomal DNA of every cell
throughout the body, and in all individuals within
the same species. Since most endogenous viruses are
non-infectious and non-replicative in the original
host, they do not induce any harm to the host. Most
endogenous viruses are defective and present as
non-expressing genes, while they occupy over 1% of
mammalian genome, even in the human species.
Infectious viruses spread in animals by transmissions
between individual hosts. The retrovirus is usually
speciﬁc to cells within a certain branch of cell
diﬀerentiations, such as CD4D T-cells in case of
HTLV-1. Unlike most other viruses, the retrovirus
remains in the body lifelong once the infection is
established, even after the viral replication is ceased
by immune responses of the host. The virus is present
only in infected cells within the infected individual,
mostly in the form of proviral DNA.
Vertical and horizontal transmission
of microorganism
Vertical transmission is the transmission from a
parent to child. Vertical transmission in a narrow
sense is the transfer of a microorganism from parent
to child before delivery. Because transmission asso-
ciated with sperm is rare, except for endogenous
retroviruses, the vertical transmission nearly equals
to MTCT. Horizontal transmission is a mode of
transmission between individuals, i.e., after the
birth. However, the vertical transmission in a broad
sense includes the transmission soon after birth,
because discrimination is not always possible. Herpes
viruses can be transmitted from mother to fetus
in utero, at the time of delivery, or postnatally. If a
child were sick at the time of delivery, it is easy to
postulate in utero transmission. Transmission at the
time of delivery may induce serious disease shortly
after the delivery, typically within a week or two.
If the sign of infection became evident at 6 months
after delivery, it is not easy to specify the time of
transmission depending on the virus concerned. As
a result, all these maternal transmissions could be
categorized as vertical in a broad sense. Most body-
ﬂuids transferred postnatally from mother to child,
such as blood and saliva, are not speciﬁc for mother-
to-child or intrafamilial transmissions. Therefore,
milk-borne transmission is the most likely candidate
in the case of MTCT for HTLV-1; however, there
were a number of uncertainties when we started the
study. Is the MTCT concept plausible? Are infected
T-cells present in breast milk of carrier mothers in
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survive through acidic conditions of the stomach?
Where is the gate of homing for the infected T-cells,
oropharyngeal lymphatic tissues, Peyer’s patches in
the intestine or else?
Most non-specialized researchers think that the
vertical transmission nearly translates to an intra-
uterine transmission. However, intrauterine trans-
mission is rather rare in the vertical transmission of
viruses. Vertical transmission of viruses in mamma-
lian species could be divided into four categories:
genetic, intrauterine, during delivery and postnatal.
Genetic transmission is the mode for endogenous
retroviruses present as proviral DNA genomes within
ovum and sperm. This is not applicable to HTLV-1.
Some viruses, such as rubella virus, human cytome-
galovirus (HCMV) and parvovirus B19, are known to
transmit through the placenta. Because trophoblasts
in placenta are the target cells of these viruses, they
tend to migrate through the placental barrier more
eﬃciently. In these cases, the evidence of intrauterine
transmission may be manifest in utero, at the time of
delivery or shortly after delivery, sometimes causing
serious disease. Even in these viruses, postnatal
transmissions are far more frequent than intrauterine
transmissions; otherwise the survival of human
species would have been diﬃcult.
For viruses circulating in the peripheral blood,
minor injuries during delivery process can cause
vertical transmissions. Because the viral titer of
hepatitis B virus (HBV) can be as high as 1012par-
ticles/mL, most babies delivered transvaginally will
be infected during delivery. Even elective cesarean
section is not helpful to shut oﬀ the transmission.
As the virus titer is usually <107particles/mL for
hepatitis C virus (HCV), only up to 10% of babies
born to HCV RNA-positive mothers will be infected.
Most of the HCV transmission might be avoided by
elective cesarean sections, but the natural history of
HCV MTCT has not been established seriously
enough to justify the procedure.12)
In animals, several infectious retroviruses had
been known, such as avian leucosis virus (ALV),
mouse mammary tumor virus (MMTV), feline
leukemia virus (FeLV), gibbon ape leukemia virus
(GaLV), Mason Pﬁzer monkey virus (MPMV) and
bovine leukemia virus (BLV). HTLV and HIV have
been added to the list in the early 1980s. Infectious or
non-endogenous ALVs in ﬂocks may behave similarly
to endogenous viruses, because the virus is already
replicating in a wide variety of embryonic cells in the
egg. MMTV is the ﬁrst tumor virus whose main
transmission pathway via breast milk was estab-
lished.13) Essentially every female C3H/He mouse
will suﬀer from breast cancer. Milk-borne trans-
mission of MMTV was proved by prophylactic foster-
nursing of female oﬀsprings to the other strain of
mice free from the MMTV. However, virions are
considered responsible for transmission, rather than
cells ﬂoating in the breast milk. FeLV is prevalent in
some households that rear a large number of cats,
sometimes up to 30%. The presence of high-titered
virus in saliva and ﬁghting between kittens were
suspected as the source of infections within the
households. Transmission of FeLV through breast
milk might be possible, but I am not aware of a report
describing the breast milk transmission. Transmis-
sion routes of simian viruses have not been studied
thoroughly, as far as I know.
Screening of pregnant women for HTLV-1
in Nagasaki
On December 01, 1980, just thirty years ago, we
started a pilot study to screen pregnant women for
anti-HTLV-1 antibody in the Nagasaki City area.
The purpose of screening was to establish a hard
evidence that mother-to-child transmission (MTCT)
is the major transmission pathway for survival of
HTLV-1 in endemic areas of Japan. A variety of
current technologies, such as polymerase chain
reaction (PCR) and commercial anti-HTLV-1 anti-
body detection kits, were yet to be available in those
days. An 8-bit personal computer on BASIC accepted
only numbers and alphabets, but not Chinese
characters to register the name and address of
pregnant women enrolled. A cassette tape recorder
was the only memory device.
Prevalence of HTLV-1 carriers in Nagasaki
We started out to survey the background
prevalence of HTLV-1 carriers in the Nagasaki area,
especially among young populations.14) The preva-
lence in medical students at Nagasaki University was
just above 1%, and that in the nurse school was
below 1% (Table 1). In order to ﬁnd the prevalence in
children, residual blood samples of pediatric patients
at the biochemistry laboratory of Nagasaki Univer-
sity Hospital were tested. As high as 5% were found
positive, but due to artifacts. At ﬁrst, we obtained
corded samples to keep conﬁdentiality. Soon, we
found that several consecutive samples were lined
positive. This was due to multiple sample tubes
originated in the same patients, and most of these
patients were leukemic who had received multiple
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patients were found antibody-positive. Furthermore,
repetitive uses of pipets in the biochemistry labo-
ratory produced contaminations to consecutive
samples. Singlet blood samples obtained from serol-
ogy laboratory without no repetitive uses of pipets
revealed a more realistic prevalence, <1%, when
leukemic patients were excluded.
Retrospective study of possible MTCT
My plan was to start the screening of pregnant
women for anti-HTLV-1 antibody in the Nagasaki
area. At the beginning, I presented my plan to Prof.
T. Miyamoto of our department, Prof. T. Yamabe of
Department of Obstetrics and Prof. Y. Tsuji of
Department of Pediatrics. They agreed to organize
the study. Prof. T. Yamabe introduced me to several
obstetric clinics and hospitals in the area. Obtaining
an informed consent from each individual was not
strict in those days. However, the purpose of the study
was explained to each pregnant woman by attending
obstetricians, because HTLV-1 was a putative leuke-
mia virus. Ethic committee was not available in the
university when we started the study. Later a
handout documenting the purpose of screening and
intervention was prepared by Nagasaki Prefecture.
Pregnant women were asked to enroll in the
screeningforanti-HTLV-1antibody.Theprevalence of
HTLV-1 carriers in pregnant women of the Nagasaki
City area was approximately 4%. Carrier mothers were
asked to bring their elder children to test if some of
them had been infected. Within a few years, we found
that the prevalence in children born to carrier mothers
was approximately 20% (Table 1). The prevalence in
children of the Nagasaki area, 1%, was roughly
consistent with the product of maternal prevalence at
4% and transmission rate of 20%. The results suggest
that carrier mothers can transmit HTLV-1 to their
oﬀsprings, and that a signiﬁcant portion of carrier
children had received the virus from their mothers.14)
A concept will become more solid if the reverse
proposition, “mothers of children carrier are carriers”,
bears out true. Among the group of pregnant women
we screened, some mothers of pregnant carriers
(grandmothers of expected babies) volunteered to
be tested their infection status. We did not recom-
mend testing grandmothers, because we did not
want to introduce additional concerns within the
family. Six of eight grandmothers were found to be
carriers.14) Both of the remaining two mothers had
been transfused, one for open heart surgery and the
other for massive bleeding at the time of previous
delivery (Table 2). The results were consistent to our
hypothesis. I felt relieved to know that some mothers
were intelligent enough to extend the concept
of vertical transmission, and that the quality of
educations given by attending obstetricians was
appropriately high.















1–10 17 78 21.8 —
Controls:
Pediatric patientsb) 0–19 14 533 2.6 <0.001
Nurse school
students
18–19 1 192 0.5 <0.001
Medical school
students
20– 7 488 1.4 <0.001
Blood donors 16–18 21 1,274 1.6 <0.001
Pregnant women 187 5,015 3.7 <0.001
a) Anti-HTLV-1 antibody was screened by the particle
agglutination assay of Fuji Rebio and conﬁrmed by the
indirect immunoﬂuorescence test.
b) Among 14 pediatric patients who were positive for the anti-
HTLV-1 antibody, 12 had received multiple transfusions for
leukemia.








Mothers of pregnant carriersa) 6b) 87 5
Mothers of carrier school childrenc) 12d) 13 92
a) Some biological mothers of pregnant carriers voluntary
wanted to know their carrier status. We did not actively
recommend the testing, because the information of carrier
status should be kept conﬁdential even in family members.
b) Both of two pregnant women whose mothers were negative
for anti-HTLV-1 had received multi-units of transfusions,
one for open heart surgery and others for massive bleeding
during the previous delivery.
c) Fifty-six children were found positive for the anti-HTLV-1
antibody among approximately 1,600 children in primary,
junior and high schools of a remote town in the Nagasaki
Prefecture. Among females in the same town who received
annual health check-ups for adults, 13 were identiﬁed as their
mothers in the town registry by the name and birth date.
d) Details unknown for the remaining mother who was
negative for the antibody.
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allowed us to use blood samples of school children
and of adults which had been collected for HBV
research coupled with annual health care program in
1960s. The town oﬃce allowed us to go through the
names and date of birth of each family member.
Among 56 carriers in school children, we found 13
mothers matched with the children carriers; 12 of
them (92%) were carriers (Table 2). Because the
reverse proposition turned out to be also true, we
were pretty conﬁdent in our working hypothesis
that MTCT was the major transmission route for
HTLV-1.14)
Postnatal transmission more likely
To conﬁrm the MTCT, carrier mothers were
asked to bring their elder siblings of the target baby.
Consistent with the working hypothesis, the preva-
lence of HTLV-1 carriers among these children was
17/78 (21.8%), signiﬁcantly higher than that of
hospitalized children and young adults in the area
(Table 1). Some of these children were followed.
Most negative children remained seronegative, whilst
small number of them seroconverted at 12 months of
age or later. The transmission incidence, at approx-
imately 20%, remained unchanged after 12 months of
age.15) In the case of intrauterine infections, such as
human cytomegalovirus and rubella virus, cord-blood
samples of infected babies are usually positive both
for virus and antibody, speciﬁcally IgM-antibody
that cannot cross the placental barrier. In case of
HBV and HCV, in which MTCT mainly takes place
at the time of delivery, high titers of these virus and
corresponding antibodies can be detected within 3
months after delivery. These results lend credence
to the postnatal transmission to the prenatal trans-
mission for HTLV-1. Late seroconversion has also
been reported by other group.16)
Possibility of intrauterine infection in HTLV-1
The possible intrauterine infection was tested in
cord-blood samples of babies born to carrier mothers.
Because all the carrier mothers were positive for IgG-
antibodies which can freely cross the placental
barrier, all these babies are antibody-positive at the
time of delivery. None of over 100 cord-blood samples
were positive for IgM-antibodies by the indirect
immunoﬂuorescence test.14) However, we could not
be certain because of a limited sensitivity of the assay
system. The PCR technology was not available at
that time. Infected cells in blood could be detected by
culturing mononuclear cells in the presence of IL-2.
We could not ﬁnd a case of positive culture in 200
cord-blood cultures from babies born to carrier
mothers, in the condition that approximately two
thirds of cultures of peripheral blood mononuclear
cells from carrier pregnant women produced positive.
However, we could not exclude the possibility of
intrauterine transmissions.
Because the maternal prevalence was approx-
imately 4%, screening of at least 5,000 pregnant
women were required to collect 200 cord-blood
samples of babies born to carrier mothers. The
existence of intrauterine infection of HTLV-1 was
controversial in those days, because there were a
few reports describing positive cord cultures from
other laboratories.17),18) Since negative studies were
more diﬃcult to convince than positive ones, many
researchers still believed the intrauterine transmis-
sion as a second transmission pathway of HTLV-1 to
breast-feeding. We decided to look for postnatal
transmission pathways.14),15)
The major pathway of MTCT
Direct transfer of the body ﬂuid is probably
required for MTCT of HTLV-1. Body ﬂuids include
blood, salivary juice, breast milk, seminal ﬂuid, urine,
stool and sweat. Contamination with the maternal
blood during delivery process is a possibility. How-
ever, in the case of infection during delivery, earlier
appearance of virus or antibody is expected. Blood
transfusion after the birth should be rare during the
normal life even with relationship of mother and
child. Salivary juice can be a candidate. However,
if salivary juice is infectious, the virus will spread
among other family members, as well as among
children in nurseries. Urine, stool and sweat were
unlikely, because live cells in these ﬂuids should be
limited in number, and transfer of a signiﬁcant
amount of them is hardly conceivable in ordinary
life styles. Seminal-ﬂuid is out of question for MTCT.
Possibility of breast milk as a source of infection
The remaining and most likely candidate was
breast milk. Although spread of retrovirus via breast
milk has been well established in case of MMTV,
HTLV-1 is transmitted probably by infected cells,
not by free virions. I had little knowledge of the
concentration of infected cells in breast milk.
Furthermore, it was not easy to postulate the
survival of infected T-cells in acidic conditions of
the stomach.
This prompted us to test the possibility of the
presence of milk-borne transmission of HTLV-1.
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the study. Breast milk samples of carrier mothers
were obtained. Surprisingly, the average concentra-
tion of cells in breast milk was as high as 106cells/mL
(Fig. 1), and approximately 90% of them were
macrophages. After culture of mononuclear cells,
puriﬁed by the Ficoll/Conray method, 0% to 10%
of cells were found HTLV-1 antigen-positive, i.e.,
infected with HTLV-1. Thus, the average number
of HTLV-1 infected cells in every milliliter of breast
milk derived from carrier mothers was computed to
reach roughly 103. Because a baby can take a liter
of breast milk a day, and will be breast-fed at least
for 100 days, the total amount of breast milk a baby
ingests will be over 100 liters, and the number of
infected cells a weanling baby can receive will exceed
108.19)
Once the presence of cells infected with HTLV-1
in the breast milk of carrier mothers was conﬁrmed
with a dose quantitatively enough for establishing
the infection, the next step was to obtain a hard
evidence that the oral intake of infected cells can lead
to infection. Most easily conceivable locations for
homing of infected maternal T-cells in the baby are
oropharyngeal lymphatic tissues or intestinal Peyer’s
patches. One of the major questions was if infected
cells in breast milk can survive through the acidic
condition in stomach of babies. Although some
colleagues stated that stomach of babies should be
less acidic than in adults, we knew that milk thrown
up by babies is usually coagulated, suggesting the
acidic condition of stomach even in newborn babies.
Lymphocytes within the coagulated milk may survive
even in the acidic condition. If the target location is
oropharyngeal lymphatic tissues, the acidic barrier
in the stomach is irrelevant. But I could not work out
an experimental system to disclose the port of entry.
Because experiments in human babies are out
of question, we started to seek out animal species
for experimental infections. Preliminary experiments
with mice and rats were not hopeful. A veterinarian
friend taught me that handling of guinea pig babies
is extremely diﬃcult. Transfusion experiments of
HTLV-1 in rabbits had been reported by Prof. I.
Miyoshi,20) but we wanted to try experiments in
primate species, closer to human species. However,
presence of antibody against simian T-lymphotropic
virus (STLV) was reported in some of Old World
monkeys, which might interfere with the diagnosis
of experimental infection.21) The age of separation
of Africa and South America was estimated at 115–
125m.y,22) much older than that of separation of
human and African apes at 4–5m.y.23) We decided
to use common marmosets, commercially available
New World monkeys, hoping that they had not been
contaminated with STLV and that they are suscep-
tible to HTLV-1. Because preparation and handling
of baby marmosets were extremely diﬃcult, adult
marmosets were used in experiments. Our boss, Prof.
T. Miyamoto, allowed us to invest a fairly large size
of money to buy marmosets and caging systems to
start the infection experiment in primates, before
outside research funds became available. We were
lucky that the construction of a brand new building
for animal experiments was just ﬁnished in the
Medical School. After arrival of the marmosets, I
was relieved to ﬁnd that none of four marmosets we
bought had the antibody reacting with HTLV-1.
Marmosets were fed with concentrated cell
suspension to mimic breast-feeding using a 1-mL
plastic syringe without needle. Because it took at
least four weeks for culture to estimate the number
of infected cells in breast milk, it was impossible to
control the infection dose by breast milk. We ﬁrst
inoculated MT-2 cells producing a large amount of
HTLV-1 to control the inoculum size of infected cells.
In total, 7 # 107 cells were given in several separate
Fig. 1. Histogram of cell concentrations in breast milk from
carrier mothers. Morphologically, 90% of them were macro-
phages. Roughly 1% of Ficoll/Conray-puriﬁed mononuclear cells
were producing HTLV-1 antigens after culture for 4 weeks.
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of two marmosets started to show serum antibody
activities against HTLV-1 by the indirect immuno-
ﬂuorescence test and by the immunoprecipitation
test using 35S-labled HTLV-1 antigens. The culture
of peripheral blood was positive for infected cells, and
the marmoset remained positive for years. The other
marmoset remained negative both in culture and
for antibodies. This proved that the oral intake of
infected cells can establish HTLV-1 infection with the
dose of <1 # 108 infected cells in common marmo-
set.19)
In the second step, two more marmosets were
inoculated with concentrated cell suspension from
fresh breast milk donated by carrier mothers (Fig. 2).
Again one of the two marmosets gained the
seroconversion and positive cultures at 2.5 months
after the ﬁrst inoculation. This conﬁrmed the work-
ing hypothesis that HTLV-1 can be transmitted by
oral intake of breast milk from carrier mothers to
their babies.24) This was supported by a retrospective
analysis of babies born to carrier mothers in whom
none of 10 completely bottle-fed babies had been
infected.25) Recently, Hisada et al. reported that the
higher concentration of the HTLV-1 infected cells in
breast milk is signiﬁcantly associated with the higher
risk of milk-borne transmission of HTLV-1.26) By the
way, because these infected marmosets were males,
milk-borne transmissions of HTLV-1 in marmosets
could not be examined.
Preparations for the intervention study
The last and ﬁnal stage to study the signiﬁcance
of MTCT in the HTLV-1 endemy was an interven-
tion, by stopping breast-feeding by carrier mothers
and to look for the lack of transmission. Our
hypothesis will be proven if the refraining from
breast-feeding in carrier mothers signiﬁcantly reduces
the incidence of MTCT. Theoretically, I thought this
intervention study not diﬃcult, because we were not
administering any additional chemicals to babies
except for the requirement of formula-feeding. How-
ever, we encountered several serious diﬃculties to
start the actual intervention study.
The most important hurdle was the nationwide
project to recommend breast-feeding. The program
was strongly supported by obstetricians, pediatri-
cians and psychologists, and by the government.
Medically, breast-feeding has been described of its
importance by several reasons. The IgA-antibody in
breast milk is the major source of maternal immuno-
logical protection of babies from respiratory and
intestinal infections. Bottle-feeding has been inferred
as a risky practice in developing countries, because
as many as a third of babies can be lost after
malnutrition and infectious diarrhea. These factors
are not critical in contemporary Japan. A large
number of children have been raised with bottle-
feeding without serious drawbacks. If a baby has
serious immunological or other problems, responsible
underlying conditions might be more important than
the HTLV-1 infection. Another concept is that good
mother-to-child relation is only formed by breast-
feeding. They say that the good relations between
mother and children were lost in the history when
most mothers in Western countries started to choose
bottle-feeding due to cosmetic reasons in 1960s. The
ﬁrst response I received at the local government,
when I visited to explain our plans, was that “the
local government can not endorse our plan because
the plan is against the national project”. He added
that “he could help us if the Department of Health,
the national government, authorized our plan.”
Another aspect was that it seemed almost
impossible to keep the conﬁdentiality of maternal
carrier status from their family members and
neighbors, if they would not breast-feed the baby.
Some carrier mothers wanted to keep the information
secret from their mothers-in-law. Later, it was found
Fig. 2. Concentrated fresh human-milk cells donated by carrier
mothers were inoculated orally in separate doses to common
marmosets by plastic syringes without needle. Abscissa: months
after ﬁrst inoculation, Ordinate: total numbers of cells inocu-
lated (bars); antibody titers against HTLV-1 antigen determined
by the indirect immunoﬂuorescence test (dots).
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especially those residing in rural areas, chose breast-
feeding because of conﬁdentiality from family mem-
bers and local community. Some obstetricians and
pediatricians instructed mothers not to bottle-feed,
because breast-feeding is important than anything
else and the incidence of ATL among carriers is rare.
They believed a newspaper describing the predictive
incidence of ATL at “90.1%”. However, the real
incidence is “90.1% per year”, which computes
“95% in life”.
Severity of health problems incurred by ATL
was not widely understood by doctors in those
days even in Nagasaki. Most doctors practicing
in obstetrics or pediatrics had never seen ATL
patients. Some nurses knew ATL better than doctors
in private clinics, because the group of nurses in the
clinic exchanged health information of their elder
family members: some of them lost family members
from ATL.
Our small pilot study induced some confusion in
obstetricians and mothers in the Prefecture, because
mothers started to realize diﬀerences in information
depending on obstetricians they visited. It took
almost a year and a half to persuade doctors within
the University and in practice at Nagasaki, as well as
the local government, to start on a prefecture-wide
intervention study. One of the important leaders
outside of the university who organized this project
was Dr. S. Miyauchi, the former Nagasaki Prefecture
Branch Secretary of Japan Association for Maternal
Welfare. Some doctors and people in Nagasaki were
really enthusiastic to start the ﬁrst in the world
experiment, named ATL Prevention Program (APP)
Nagasaki, because they wanted to keep the ambition
that Nagasaki has cherished to become the leader
in medical science of Japan. Nagasaki University
started as the ﬁrst medical school of Western
medicine in Japan, since Nagasaki was the only port
in Japan open to Western cultures for 9200y until
1850s. Before actually starting the project, we gave a
series of lectures introducing the system of the APP
Nagasaki to obstetricians and health practitioners in
the Nagasaki Prefecture.
The APP Nagasaki was commenced in July of
1987 in the whole Nagasaki Prefecture harboring
a population of 1.5 million. Pregnant women were
screened for anti-HTLV-1 antibody during the last
trimester for the anti-HTLV-1 antibody. The last
trimester was selected to minimize artiﬁcial abortions
because of realizing the carrier status of HTLV-1.
Fuji Rebio’s particle agglutination assay was used for
screening at commercial laboratories. All the positive
and undetermined samples were collected and sent to
our department to standardize the prefecture-wide
diagnosis. This was found important, since some
commercial laboratories reported false-positive re-
sults more often than others. The conﬁrmation test
consisted of titration of the anti-HTLV-1 antibody
with the particle agglutination method and an
indirect immunoﬂuorescence test. Later, the western
blot assay was added for the conﬁrmation.
Pregnant women with positive results conﬁrmed
were informed as HTLV-1 positivity and recom-
mended to refrain from breast-feeding. Children born
to carrier mothers were asked to come back for blood
test at 6, 12, 24 and 36 months after the delivery
to examine possible infection. The purposes of the
follow-up study were to estimate the MTCT in-
cidence of HTLV-1, and to ﬁnd out an appropriate
time point after the delivery for the diagnosis of
MTCT. Mothers were able to select breast-feeding, if
they wanted to do so. If they chose it, we informed
them that infected cells in breast milk can be
inactivated by heat treatment at 60°C for 30min,
or by freezing overnight. However, we strongly
recommended the total abolishment of breast-feed-
ing, because treatment of suctioned milk should be
continued until weaning and the practice will not
merit direct suckling with the baby during breast-
feeding. Most carrier mothers who selected bottle-
feeding received bromocriptine to minimize the
unpleasant experience with breast milk production.
Prevalence of HTLV-1 carriers among
pregnant women in Nagasaki
When we started the screening in the early
1980s, the prevalence of HTLV-1 carriers among
pregnant women was approximately 5%, it declined
to 1% level in the last decade (Fig. 3).27) The total
number of deliveries in the Nagasaki Prefecture also
declined recently. The number of declined from
915,000 in 1987 to 912,000 in the last decade.
Approximately three quarters of pregnant women
were enrolled to the APP Nagasaki during this
period. The decrease was consistent with the general
tendency of fewer children in each family. The
number of carriers detected among pregnant women
dropped rather dramatically, from 91,000 to 9100 in
the same period.
This eﬀect was reﬂected in the decline of
prevalence dependent on the date of birth cohort in
pregnant women (Fig. 4). Among pregnant women
screened and born in the late 1940s through 1980, the
S. HINO [Vol. 87, 160prevalence declined sharply with birth year. By the
slope of regression line and the period of one
generation computed by the average age of pregnant
women at 29y, the transmission rate from one
generation to another is calculated to be 24%, which
was well consistent with the average transmission rate
by breast-feeding at 920% (Fig. 4). The prevalence
in those born in 1987 was estimated at 1% from
the graph. After the commencement of the APP
Nagasaki in 1987, the decline in prevalence by cohort
eﬀect will be estimated to proceed even sharper.
Reason for the decrease is not clear, and may be
associated with a number of factors. One of likely
reasons is westernization of the community. Duration
of breast-feeding period may become shorter in these
days, because women at work tend to ﬁnish breast-
feeding early and replace for bottle-feeding. The
hygienic status has been dramatically improved to
push up the immunity against infectious agents.
Because a quarter of uninfected wives married to
infected husband will acquire HTLV-1 within several
years, larger family size in the past might have been a
factor for increased prevalence in children.
Breaking the pathway of breast-feeding
Even after commencing the APP Nagasaski,
the incidence of MTCT with HTLV-1 continued to
remain at the level of 20% among mothers who chose
Fig. 3. Screening of pregnant women for the anti-HTLV-1
antibody by the ATL Prevention Program Nagasaki commenced
in 1987. Numbers of deliveries in the Nagasaki Prefecture,
pregnant women screened, carriers detected and the prevalence
of carrier women in each year are shown. Data were taken from
the reference26) with permission of the Prefecture and authors.
Fig. 4. Birth-cohort eﬀect on the prevalence of HTLV-1 carriers
among pregnant women in the Nagasaki Prefecture. The dotted
line estimates sharper decline of the prevalence after the start of
APP Nagasaki.
Table 3. Eﬀects of feeding practice on mother-to-child infection
of HTLV-1 in children born to carrier mothers in terms of bottle









Bottle-feeding 1,152 29 2.5 —b)
Breast-feeding
<6 months 202 15 7.4 <0.001 —b)
66 months 365 74 20.3 <0.001 <0.001
a) Prospectively followed cases only, born in the period from
1987 to 2004. Data were taken from the reference27) with
permission of the Prefecture and authors.
b) Base category being compared with.
Milk-borne transmission of HTLV-1 No. 4] 161breast-feeding.28),29) Some gynecologists/pediatri-
cians still strongly recommended breast-feeding than
anything else. Some of mothers might be afraid of
revealing their carrier status to their family members
and/or neighbors, by refraining of breast-feeding. By
shutting oﬀ the breast-feeding by carrier mothers,
the MTCT dropped to the level of 2.5%, which was
signiﬁcantly lower than that in the group breast-fed
66 months (P 5 0.001) (Table 3). The results were
consistent with a working hypothesis that breast milk
is the major route of the MTCT with HTLV-1 in the
endemic area.
Reduction of HTLV-1 infection
by short-term breast-feeding
In the meantime, other groups reported that
early withdrawal of breast-feeding will decrease the
incidence of MTCT signiﬁcantly.26),30),31) Takahashi
et al.30) described that the transmission rates of short-
term (56 months) and long-term (>6 months)
breast-feeders were 4.4% (4/90) vs. 14.4% (20/139),
P F 0.018. They further wrote that the seroconver-
sion rate of short-term breast-fed children was nearly
equal to that of bottle-fed children; (4.4% [4/90] vs.
5.7% [9/158], P F 0.471). Instead, they should have
described the lack of signiﬁcant diﬀerences between
short-term breast-fed and bottle-fed children, prob-
ably due to the small sample size. The statement they
posted implied that short-term breast-feeding is as
safe as bottle-feeding without any scientiﬁc evidence.
Furthermore, most of children breast-fed for short-
term or long-term were enrolled retrospectively, and
we know that informations of breast-feeding period
for previously born children are not very reliable.
A newspaper dared to report no diﬀerences in the
incidence of HTLV-1 infection between short-term
breast-feeders and bottle-feeders, and many doctors
even in the Nagasaki area believed the news.
Hirata et al. reported that bottle-fed children,
breast-fed 53 months and >3 months had the
incidence of infection in 12.8% (10/78), 5.1% (2/37)
and 27.6% (16/42): an incidence in bottle-fed
children higher than that in short-term breast-fed
children was hard to explain except for statistical
insigniﬁcance due to the small sample size.31) They
implicated the association of anti-p40tax antibody
with the high risk of vertical transmission of
HTLV-1; however, the notion was denied in another
report.26) Another group reported similar observation
of the infection in 2.5% (4/162), 3.9% (2/51) and
20.3% (13/64) in children with bottle-feeding, breast
feeding for 56 months and for >6 months, respec-
tively.32) The infection in bottle-fed and short-term
breast-fed children was signiﬁcantly lower than that
in long-term breast-fed children. However, the diﬀer-
ence in incidence between bottle-fed and short-term
breast-fed children was insigniﬁcant, because of the
small sample size of studied children. The breast-fed
children for the short-term resulted in the incidence
of MTCT lower than the breast-fed children for the
long-term (P F 0.021, by the chi-squared test with
the Yates’ correction).33) However, some breast-fed
children for the short-term seroconverted after the
paper was submitted in a personal communication
from one of the authors. Nevertheless, none of these
reports were conﬁrmed with the extension of follow-
up data since then.
The APP Nagasaski kept the position to
recommend bottle-feeding than short-term breast-
feeding, because accumulating lines of evidence kept
suggesting that the former is safer than the latter,
although the data did not reach the statistical
signiﬁcance due to a small sample size. In 2008, the
Nagasaki Prefecture and the APP Nagasaki published
a recent report as “Report of joint study on the
prevention of ATL by blocking mother-to-child
transmission of HTLV-1: experiences and perspec-
tives of 20 years”.27) The data conﬁrmed the incidence
of HTLV-1 infection in the bottle-fed children was
signiﬁcantly lower than that in the breast-fed children
for long-term (breast-fed for 66 months) (2.5% vs.
20.3%, P < 0.001) (Table 3). Among breast-fed chil-
dren, the incidence was signiﬁcantly lower in those
breast-fed for short-term (<6 months) than that in
those for the long-term (7.4% vs. 20.3%, P < 0.001),
consistent with our previous reports.28),29) However,
the signiﬁcantly higher incidence in the short-term
group than that in the bottle-fed group was clearly
established in this recent report (7.4% vs. 2.5%,
P < 0.001).27) The information spread through news-
paper was found untrue, because the interpretation of
previous papers was not scientiﬁc. Although children
breast-fed for <6 months has signiﬁcantly lower
incidence of HTLV-1 infection than those breast-
fed for 66 months, their chances of infection are
signiﬁcantly higher than those of bottle-fed children.
Thus, the APP Nagasaki is keep recommending the
exclusive bottle-feeding for carrier mothers.
Secondary pathway of MTCT
Even with complete bottle-feeding, 2.5% of
babies born to carrier mothers were infected. Cord-
blood samples of babies born to carrier mothers were
tested for the HTLV-1 provirus by PCR. A short
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4% of samples, and most positive signals were found
to represent defective proviruses.34),35) Although in a
small scale of cases, none of babies PCR-positive in
the cord-blood kept the positive signal at 6 months
after the delivery. On the other hand, none of babies
who were diagnosed with infection beyond 12 months
of age had been PCR-positive in their cord-blood
(Table 4). These results suggest that intrauterine
transmission of HTLV-1 should be rare, if any. The
results were consistent with our early observations
that none of cord-blood samples were positive for
HTLV-1 with neither IgM-antibody nor HTLV-1
antigen in culture. I prefer transmission during the
delivery to transplacental transmission, as is the case
for other viruses, such as HBV and HCV.12)
Is it possible to eliminate HTLV-1
from the endemic area?
Even without interventions, sooner or later,
HTLV-1 will be eliminated from the endemic area.
A large number of Japanese were emigrated from
endemic areas, for example to Hawaii, California,
Canada and South America. However, HTLV-1 is
not markedly endemic among Japanese descendants
in those districts any longer. Even in Nagasaki, the
prevalence among pregnant women was approxi-
mately 5% in the early 1980s, but declined to 1% in
the last decade (Fig. 3). This decline is not related to
our intervention, because they had been born before
commencing the APP Nagasaki. When the preva-
lence in pregnant women was analyzed by birth
cohorts, the carrier rate decreased linearly in the
logarithmic scale during the era without intervention
(Fig. 4). The slope indicated that the prevalence
decreased to 24% in each generation when the
generation time was computed as 29 years using the
average age of pregnant women in the APP study.
The rate of decline was consistent with the observed
rate of MTCT with long-term breast-feedings at
approximately 20%.
By the end of 2006, >200,000 screening tests
were performed for the detection of HTLV-1 carriers
which covered approximately 74% of total pregnan-
cies in the Nagasaki Prefecture during the period, and
7,265 tests were positive (3.5%)27) (Table 5). Since
approximately 90% of the positive mothers agreed to
refrain from breast-feeding to minimize the chance
of HTLV-1 transmission, approximately 6,500 chil-
dren born to carrier mothers were bottle-fed in the
intervention by the APP Nagasaki. The transmission
rate was calculated to be 24% from the slope of
reduction of carrier women calculated from birth
cohort (Fig. 4), and the transmission rate of bottle-
feeding was 2.5% (Table 4), approximately 20%
of putative transmission was blocked by the APP
Nagasaki. Therefore, it can be estimated that
approximately 1,300 potential transmissions and
260 potential ATL cases in future were prevented
in Nagasaki by the year 2006. Because the prevalence
of pregnant carrier has been declining, the number of
these protected cases will also decline in the future.
Table 4. HTLV-1 infection markers, antibody and PCR, in cord-
blood at birth and of peripheral blood at 6 or 612 months of age
ID of case
Cord blood at 6 months at 612 months
Ab PCR Ab PCR Ab PCR
1 DD !nta) !!
2 DD !nt !!
3 DDnt nt !!
4 DD D! ! nt
5 DD D! nt nt
6 D! !nt DD
7 D!nt nt DD
8 D! Dnt D nt
9 D! !nt D nt
a) nt: not tested.
Table 5. Summery of APP Nagasaki: Screening and prospect
Estimated No. cases Calculated













ATL incidence in futured) 5% 260
a) Calculated from the decline of HTLV-1 carriers among
the birth cohort of pregnant women (see Fig. 4). The value
presented in Table 3 is 20.3% which is represented by much
smaller number of samples.
b) See Table 3.
c) Rounded from the calculation of 24% ! 2.5%, in a) and b).
d) The average life-time incidence of ATL among carriers: ca.
5%.9),36)
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New ATL cases have been developing among
HTLV-1 carriers.36) To minimize the further expan-
sion of the carrier pool, introduction of eﬀective
measures has been awaited outside of the Nagasaki
Prefecture. In October, 2010, the nationwide screening
policy of pregnant women for HTLV-1 has been
announced,37) but details are unknown. In our
experiences, there are several potential problems
for the program. Education of obstetric doctors is
essential. If attending doctors do not understand
the severity of ATL, it is diﬃcult to deliver the
appropriate information for pregnant women and to
persuade them diagnosed positive toward refraining
from breast-feeding. Most obstetricians and pediatri-
cians, especially those in non-endemic areas, have no
experiences with ATL. Most of them may think ATL
would be treatable in the current medical standards,
just like the other leukemias, and the incidence of ATL
among carriers would be rare. In our experiences, most
pregnant women visiting certain doctors selected
breast-feeding rather than bottle-feeding, probably
because they recommend breast-feeding as the most
important tool forrearing babies. On the other hand, if
mothers in non-endemic areas do not breast-feed their
baby, their carrier status may be revealed in the
community just because of bottle-feeding. It must be
reminded that eﬀorts for community education were
far from the satisfactory level, even for HIV. If carrier
mothers do not refrain from breast-feeding, the
program will only be a political excuse.
Consideration for cost performance
of the screening
Costs of anti-HTLV-1 antibody detection for
screening and conﬁrmation are approximately
2,000JYE and 5,000JYE, respectively. Since the
prevalence is usually less than 5%, the total cost
is mainly dependent on the screening level. The
incidence of HTLV-1 infection among breast-fed
children and that of ATL among carriers are
computed as approximately 20% and 5% during the
life. When we started the APP Nagasaki in the late
1980s, the average prevalence was 4%. The computed
costs for detecting a HTLV-1 carrier, for preventing
an infection and for reducing a case of ATL develop-
ment were 50,000, 250,000 and 5,000,000JYE,
respectively. In 2010, the average prevalence dropped
to the 1% level even in Nagasaki, the screening cost
increased by four-fold. In non-endemic areas with the
prevalence of 0.1%, the screening cost will be 40-fold
of that originally computed in Nagasaki 30y ago, i.e.,
200,000,000JYE to prevent a case of ATL that might
develop one half century later.
Risk of false diagnosis
False positive and false negative diagnoses can
happen. If the false positive diagnosis occurs in 0.1%
of tested, and the real prevalence is 5%, the incidence
of false diagnosis among real positives is limited to
2%. However, in the area with real prevalence of 0.1%
(most areas outside of Kyushu have the prevalence
below this level), as much as one half of pregnant
women diagnosed to be positive can be false positive.
Notice of HTLV-1 carrier status itself can induce a
strong trauma, and positive mothers are forced to
decide the feeding method. I do not know how the
government has decided to carry out the conﬁrma-
tion test. It should be performed at accredited
institutions. Because positive samples will be rela-
tively rare, especially in non-endemic regions, con-
ﬁrmation tests performed at small local laboratories
are not reliable, which may further increase the rate
of false positives. It is likely that the government
will pay for the screening, but who will pay for the
conﬁrmation test which is more expensive than
screening? If the conﬁrmation test will not be
covered, screened positives may be hardly to be
conﬁrmed. I hope the program will be commenced
without much confusion.
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